Another Canadian patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the The Canadian Intellectual Property Office (CIPO).

The patent, entitled “Design method of a rig”, is within the area of individualised surgical instruments with a focus on the drill guide for the Episealer® Femoral Twin implant.

“This is another patent strengthening Episurf’s technology within individual solutions for the patients, with a focus on the company’s most popular device Episealer® Femoral Twin”, comments Katarina Flodström, CRO & Head of IP, Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.30 CET on 27 February 2019.

Tags: